Clinical Trials Logo

Advanced or Metastatic NSCLC clinical trials

View clinical trials related to Advanced or Metastatic NSCLC.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05941897 Active, not recruiting - Clinical trials for Advanced or Metastatic NSCLC

A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy

LOTOS
Start date: June 21, 2023
Phase: Phase 2
Study type: Interventional

A study to investigate efficacy and safety of ceralasertib plus durvalumab in participants aged ≥ 18 years with advanced or metastatic non-small cell lung cancer whose disease progressed on or after prior anti-PD-(L)1 therapy and platinum-based chemotherapy.

NCT ID: NCT04526691 Active, not recruiting - Clinical trials for Advanced or Metastatic NSCLC

Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

Start date: September 15, 2020
Phase: Phase 1
Study type: Interventional

This study will assess safety and treatment activity of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy in participants with advanced or metastatic non-small cell lung cancer.